HER2-POSITIVE BREAST CANCER
Clinical trials for HER2-POSITIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HER2-POSITIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for HER2-POSITIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Egyptian breast cancer study tests targeted drug effectiveness
Disease control CompletedThis study followed 80 Egyptian women with HER2-positive breast cancer to see how well anti-HER2 drugs work in real-world treatment. Researchers observed patients receiving either single drugs or drug combinations as part of their standard care, tracking survival, side effects, a…
Matched conditions: HER2-POSITIVE BREAST CANCER
Sponsor: Deraya University • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
New drug duo fights Tough-to-Treat breast cancer
Disease control CompletedThis study tested a combination of two targeted drugs, tucatinib and trastuzumab deruxtecan, for people with advanced HER2-positive breast cancer that had spread or could not be removed by surgery. The main goal was to see how well the combination worked to shrink tumors and cont…
Matched conditions: HER2-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
Tracking a new drug Combo's Real-Life impact on advanced breast cancer
Disease control CompletedThis study observed how well a drug combination (tucatinib with trastuzumab and capecitabine) worked for 49 adults in Germany and Austria with advanced HER2-positive breast cancer that had worsened after at least two prior treatments. The main goal was to see how the treatment af…
Matched conditions: HER2-POSITIVE BREAST CANCER
Sponsor: iOMEDICO AG • Aim: Disease control
Last updated Mar 12, 2026 13:52 UTC
-
Study tracks Real-World use of advanced breast cancer drug
Knowledge-focused CompletedThis study observed how patients with advanced HER2-positive or HER2-low breast cancer used the drug trastuzumab deruxtecan (T-DXd) in routine Canadian clinics. Researchers tracked 22 patients to see how often treatment was stopped early or doses were changed, and how long patien…
Matched conditions: HER2-POSITIVE BREAST CANCER
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Apr 01, 2026 21:41 UTC
-
Researchers review Real-World data on breast cancer drug
Knowledge-focused CompletedThis study looked back at medical records to understand the types of patients who received the drug neratinib for early-stage HER2-positive breast cancer in Europe. It involved 111 patients who had already taken the drug as part of a special access program. The goal was to descri…
Matched conditions: HER2-POSITIVE BREAST CANCER
Sponsor: Pierre Fabre Medicament • Aim: Knowledge-focused
Last updated Mar 23, 2026 15:16 UTC